Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans.
BACKGROUND
The incidence of vulvovaginal candidiasis, a common infection among healthy women primarily caused by the yeast Candida albicans, has increased significantly in recent years.


OBJECTIVE
The purpose of this study was to compare the efficacy of ravuconazole (RVC) and fluconazole (FLC) in the treatment of experimental C. albicans vaginitis.


METHODS
Forty isolates of C. albicans were screened for their in vitro susceptibility to RVC and FLC. A strain of C. albicans that was resistant to FLC (minimum inhibitory concentration [MIC] of >64 μg/ml) was selected for the in vivo study. Treatment regimens for the murine vaginal infection model were (1) 1, 5, 10, and 20 mg/kg RVC once daily, (2) 20 mg/kg RVC twice daily, (3) 20 mg/kg FLC once daily, and (4) 20 mg/kg FLC twice daily.


RESULTS
The geometric means of the MIC values at 48 h for all isolates tested were 0.05 and 0.5 μg/ml for RVC and FLC, respectively. Regimens of either RVC or FLC at 20 mg/kg twice daily were more effective to reduce the load of FLC-resistant C. albicans than single dose administration.


CONCLUSIONS
Complete eradication of C. albicans from the vagina was not observed with RVC or FLC treatment in the animal model, although RVC treatment showed a lower fungal concentration 14 days after drug administration.
Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Departamento de Microbiología, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico.
Mariana
M
Elizondo-Zertuche
Universidad Autónoma de Nuevo León, UANL, Facultad de Ciencias Biológicas, Av. Universidad S/N Ciudad Universitaria, San Nicolás de los Garza, Nuevo León, C.P. 66451, Mexico.
Efrén
E
Robledo-Leal
Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Hospital Universitario Dr. José Eleuterio González, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico.
J Gerardo
JG
González
Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Hospital Universitario Dr. José Eleuterio González, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico.
Luis A
LA
Ceceñas
Universidad Autónoma de Nuevo León, UANL, Facultad de Medicina, Departamento de Microbiología, Av. Francisco I. Madero y calle Dr. E. A. Pequeño S/N, Colonia Mitras Centro, Monterrey, Nuevo León, C.P. 64460, Mexico. Electronic address: gmglez@yahoo.com.mx.
Gloria M
GM
González
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D025141:Drug Resistance, Fungal; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D023421:Models, Animal; D011897:Random Allocation; D013045:Species Specificity; D013844:Thiazoles / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D013844:Thiazoles; D014230:Triazoles; D015725:Fluconazole; C104066:ER 30346
Candida albicans; Candidiasis; Eficacia terapéutica; Ravuconazol; Ravuconazole; Therapeutic efficacy; Vaginitis